Phase I Trial of Adaptive Stereotactic Body Radiotherapy (SBRT) Dose Escalation in Pancreatic Cancer
Summary
The purpose of this phase I study is to determine the maximum tolerated dose (MTD) of five fraction stereotactic radiotherapy (SBRT) in pancreatic cancer.
General Information
NCT#: NCT02454140
Study ID: 140103
Trial Phase: Phase I
Trial Sponsor: University of California, San Diego
Therapies Used in This Trial: Stereotactic body radiotherapy (SBRT)